Panthera supports clinical trials via recruitment and management of patients through the trial process
Patient recruitment and retention has been a major pain point in trials and the development of novel drugs, and Panthera’s contribution to medical research and the advancement of medical interventions aims to ensure that future generations receive the very best in new treatments.
Its research sites operate across the UK, with clinics in London, Preston, Manchester, and Glasgow with more planned.
Gresham House Ventures provided Series A funding alongside Catapult Ventures in 2020. We participated in a £10mn follow-on funding round in April 2022, alongside BGF.
Investment rationale
The funding will ensure Panthera has the backing to provide pharmaceutical clients and patients with an exemplar service – the vision of both founders.
In August 2025, we successfully exited our investment in Panthera Biopartners following a significant growth journey.
